Spot urinary sodium in acute decompensation of advanced heart failure and dilutional hyponatremia: insights from DRAIN trial.
Administration, Intravenous
Aged
Biomarkers
/ metabolism
Diuretics
/ administration & dosage
Double-Blind Method
Drug Resistance
Female
Furosemide
/ administration & dosage
Heart Failure
/ drug therapy
Humans
Hyponatremia
/ epidemiology
Kidney Function Tests
Male
Middle Aged
Natriuresis
/ drug effects
Natriuretic Peptide, Brain
Peptide Fragments
Prospective Studies
Sodium
/ urine
Treatment Outcome
Acute heart failure
Advanced heart failure
Diuretic resistance
Hyponatremia
Natriuretic peptides
Journal
Clinical research in cardiology : official journal of the German Cardiac Society
ISSN: 1861-0692
Titre abrégé: Clin Res Cardiol
Pays: Germany
ID NLM: 101264123
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
received:
13
10
2019
accepted:
03
02
2020
pubmed:
8
3
2020
medline:
24
7
2021
entrez:
8
3
2020
Statut:
ppublish
Résumé
Diuretic resistance portends a poor prognosis in acute heart failure, especially in advanced stages. Early identification of a poor response to diuretics may help to improve treatment and outcomes. Spot natriuresis (UNa We performed a sub-analysis of the DRAIN trial, a randomized clinical trial on 80 patients with acute decompensation of ACHF (NYHA IV, EF ≤ 30%) with low systolic blood pressure (≤ 110 mmHg) and dilutional hyponatremia (sodium ≤ 135 mMol/L) at admission. Patients were divided into two groups according to spot urinary sodium excretion (high: UNa In patients with ACHF and dilutional hyponatremia, low natriuresis after furosemide is an early marker of poor diuretic response and correlates with higher NT-proBNP and higher incidence of worsening renal function at 72 h.
Sections du résumé
BACKGROUND
BACKGROUND
Diuretic resistance portends a poor prognosis in acute heart failure, especially in advanced stages. Early identification of a poor response to diuretics may help to improve treatment and outcomes. Spot natriuresis (UNa
METHODS AND RESULTS
RESULTS
We performed a sub-analysis of the DRAIN trial, a randomized clinical trial on 80 patients with acute decompensation of ACHF (NYHA IV, EF ≤ 30%) with low systolic blood pressure (≤ 110 mmHg) and dilutional hyponatremia (sodium ≤ 135 mMol/L) at admission. Patients were divided into two groups according to spot urinary sodium excretion (high: UNa
CONCLUSIONS
CONCLUSIONS
In patients with ACHF and dilutional hyponatremia, low natriuresis after furosemide is an early marker of poor diuretic response and correlates with higher NT-proBNP and higher incidence of worsening renal function at 72 h.
Identifiants
pubmed: 32144493
doi: 10.1007/s00392-020-01617-w
pii: 10.1007/s00392-020-01617-w
doi:
Substances chimiques
Biomarkers
0
Diuretics
0
Peptide Fragments
0
pro-brain natriuretic peptide (1-76)
0
Natriuretic Peptide, Brain
114471-18-0
Furosemide
7LXU5N7ZO5
Sodium
9NEZ333N27
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
1251-1259Commentaires et corrections
Type : ErratumIn